Alliance Member-Only Meeting with Dr. Peter Marks, FDA’s CBER

Peter Marks, MD, PhD, director of the Center for Biologics Evaluation and Research (CBER) at FDA, joined us for a members-only alliance discussion to discuss efforts to shape a robust, cost- and time-efficient regulatory review pathway for advances in gene therapy. Offering unimagined hope for the treatment and cure of rare childhood diseases and other treatment-elusive health threats, gene therapy is one of the most promising, and challenging, areas of focus for 21st century science. This was a members-only, off-the-record discussion.